Liver expression of matrix metalloproteases and their inhibitors in hepatocellular carcinoma

Digestive and Liver Disease

Volumn 41, Issue 10, 2009, Pages 740-748

  Altadill, A ^a   Rodriguez M ^b   Gonzalez L O ^a,c   Junquera, S ^a   Corte, M D ^a   Gonzalez Dieguez M L ^b   Linares, A ^b   Barbon E ^a   Fresno Forcelledo, M ^b   Rodrigo, L ^b   Vizoso, F J ^a,c  

^a HOSPITAL DE JOVE   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

Hepatocellular carcinoma (HCC); Matrix metalloproteases (MMPs); Prognosis; Tissue inhibitors of metalloproteinases (TIMPs)

Indexed keywords

ALPHA FETOPROTEIN; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; SURVIVAL RATE; TISSUE MICROARRAY; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MIDDLE AGED; PROGNOSIS; STROMAL CELLS; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 69749087845     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2009.01.016     Document Type: Article

References (59)

1. Nagasue N., Uchida M., Makino Y., et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 105 (1993) 488-494
2. Yamamoto J., Kosuge T., Takayama T., et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83 (1996) 1219-1222
3. Poon R.T., Fan S.T., Lo C.M., Liu C.L., and Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229 (1999) 216-222
4. Huang M., and Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett 135 (1999) 97-105
5. Nelson A.R., Fingleton B., Rothenberg M.L., and Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18 (2000) 1135-1149
6. McCawley L.J., and Matrisian L.M. Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol 13 (2001) 534-540
7. Overall C.M., and Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2 (2002) 657-672
8. Demers M., Couillard J., Belanger S., and St-Pierre Y. New roles for matrix metalloproteinases in metastasis. Crit Rev Immunol 25 (2005) 493-523
9. Brinckerhoff C.E., Rutter J.L., and Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 6 (2000) 4823-4830
10. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17 (2001) 463-516
11. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
12. Turk V., Kos J., and Turk B. Cysteine cathepsins (proteases)-on the main stage of cancer?. Cancer Cell 5 (2004) 409-410
13. Rifkin D.B., Mazzieri R., Munger J.S., Noguera I., and Sung J. Proteolytic control of growth factor availability. APMIS 107 (1999) 80-85
14. Manes S., Llorente M., Lacalle R.A., et al. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274 (1999) 6935-6945
15. Noe V., Fingleton B., Jacobs K., et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114 (2001) 111-118
16. Fingleton B., Vargo-Gogola T., Crawford H.C., and Matrisian L.M. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3 (2001) 459-468
17. Yu Q., and Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14 (2000) 163-176
18. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103 (1999) 1237-1241
19. Dong Z., Kumar R., Yang X., and Fidler I.J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88 (1997) 801-810
20. Cornelius L.A., Nehring L.C., Harding E., et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161 (1998) 6845-6852
21. Ferreras M., Felbor U., Lenhard T., Olsen B.R., and Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 486 (2000) 247-251
22. Jiang Y., Goldberg I.D., and Shi Y.E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21 (2002) 2245-2252
23. Baker A.H., George S.J., Zaltsman A.B., Murphy G., and Newby A.C. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79 (1999) 1347-1355
24. Yamamoto H., Itoh F., Adachi Y., et al. Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology 112 (1997) 1290-1296
25. Theret N., Musso O., Turlin B., et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 34 (2001) 82-88
26. Ishii Y., Nakasato Y., Kobayashi S., Yamazaki Y., and Aoki T. A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. J Exp Clin Cancer Res 22 (2003) 461-470
27. McKenna G.J., Chen Y., Smith R.M., et al. A role for matrix metalloproteinases and tumor host interaction in hepatocellular carcinomas. Am J Surg 183 (2002) 588-594
28. Sawada S., Murakami K., Murata J., Tsukada K., and Saiki I. Accumulation of extracellular matrix in the liver induces high metastatic potential of hepatocellular carcinoma to the lung. Int J Oncol 19 (2001) 65-70
29. Maatta M., Soini Y., Liakka A., and Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 6 (2000) 2726-2734
30. Cui J., Dong B.W., Liang P., Yu X.L., and Yu D.J. Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. World J Gastroenterol 10 (2004) 1533-1536
31. Zhang Q., Chen X., Zhou J., et al. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 5 (2006) 808-814
32. Gao Z.H., Tretiakova M.S., Liu W.H., Gong C., Farris P.D., and Hart J. Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma. Mod Pathol 19 (2006) 533-540
33. Arii S., Mise M., Harada T., et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24 (1996) 316-322
34. Hayasaka A., Suzuki N., Fujimoto N., et al. Elevated plasma levels of matrix metalloproteinase-9 (92-kD type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 24 (1996) 1058-1062
35. Sakamoto Y., Mafune K., Mori M., et al. Overexpression of MMP-9 correlates with growth of small hepatocellular carcinoma. Int J Oncol 17 (2000) 237-243
36. Harada T., Arii S., Mise M., et al. Membrane-type matrix metalloproteinase-1 (MT1-MTP) gene is overexpressed in highly invasive hepatocellular carcinomas. J Hepatol 28 (1998) 231-239
37. Chen X., Cheung S.T., So S., et al. Gene expression patterns in human liver cancers. Mol Biol Cell 13 (2002) 1929-1939
38. Ip Y.C., Cheung S.T., Leung K.L., and Fan S.T. Mechanism of metastasis by membrane type 1-matrix metalloproteinase in hepatocellular carcinoma. World J Gastroenterol 11 (2005) 6269-6276
39. Llovet J.M., Bru C., and Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19 (1999) 329-338
40. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., and Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973) 646-649
41. Sorensen J.B., Klee M., Palshof T., and Hansen H.H. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67 (1993) 773-775
42. Parker R.L., Huntsman D.G., Lesack D.W., et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 117 (2002) 723-728
43. Eisen M.B., Spellman P.T., Brown P.O., and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95 (1998) 14863-14868
44. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10 (2000) 415-433
45. Akriviadis E.A., Llovet J.M., Efremidis S.C., et al. Hepatocellular carcinoma. Br J Surg 85 (1998) 1319-1331
46. Ozaki T., Mochizuki H., Ichikawa Y., Fukuzawa Y., Yoshida S., and Morimoto M. Persistence of hepatitis B surface antibody levels after vaccination with a recombinant hepatitis B vaccine: a 3-year follow-up study. J Oral Sci 42 (2000) 147-150
47. Milani S., Herbst H., Schuppan D., et al. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 144 (1994) 528-537
48. Benyon R.C., Iredale J.P., Goddard S., Winwood P.J., and Arthur M.J. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 110 (1996) 821-831
49. Kapranos N., Karaiossifidi H., Kouri E., and Vasilaros S. Nm23 expression in breast ductal carcinomas: a ten year follow-up study in a uniform group of node-negative breast cancer patients. Anticancer Res 16 (1996) 3987-3990
50. Takahara T., Furui K., Yata Y., et al. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 26 (1997) 1521-1529
51. Preaux A.M., Mallat A., Nhieu J.T., D'Ortho M.P., Hembry R.M., and Mavier P. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 30 (1999) 944-950
52. Kang Y., Siegel P.M., Shu W., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3 (2003) 537-549
53. Przybylowska K., Kluczna A., Zadrozny M., et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat 95 (2006) 65-72
54. Freije J.M., Diez-Itza I., Balbin M., et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 269 (1994) 16766-16773
55. Knauper V., Cowell S., Smith B., et al. The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 272 (1997) 7608-7616
56. Ala-aho R., and Kahari V.M. Collagenases in cancer. Biochimie 87 (2005) 273-286
57. Knauper V., Smith B., Lopez-Otin C., and Murphy G. Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). Eur J Biochem 248 (1997) 369-373
58. Roeb E., Bosserhoff A.K., Hamacher S., et al. Enhanced migration of tissue inhibitor of metalloproteinase overexpressing hepatoma cells is attributed to gelatinases: relevance to intracellular signaling pathways. World J Gastroenterol 11 (2005) 1096-1104
59. Nakatsukasa H., Ashida K., Higashi T., et al. Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas. Hepatology 24 (1996) 82-88